Introduction
Pneumonia is an important clinical condition which is commonly confronted both by a pulmonologist as well as a general practitioner. In spite of plethora of information on the subject, one often finds it difficult to make critical decisions. There are several evidencebased guidelines to guide treatment decisions. However, there are no Indian guidelines, which consider the differences in health-care organisation, prescription habits of doctors, drug availability and costs. Moreover, the clinical practice is different at different levels of health-care in the country. It was, therefore, considered important to frame evidencebased, consensus guidelines for the physicians.
(C) diagnosis of hospital-acquired, healthcareassociated and ventilator-associated pneumonia (HAP, HCAP and VAP); (D) management of HAP, HCAP and VAP, each with a Group-Chair and a Rapporteur. Important questions were framed on the basis of discussions on issues with reference to the Indian context. The available evidence, as well as the questions were circulated to all the group members before the joint workshop. Discussions for grading of evidence and recommendations were held in four different groups and thereafter together in the joint meeting of all the groups. Final decisions in the joint group were based on a consensus approach on the majority-voting.
The Modified Grade System was used for classifying the quality of evidence as 1, 2, 3 or useful practice point (UPP) [ Table 1 ]. 1 The strength of recommendation was graded as A or B depending upon the level of evidence [ Table 1 ]. Grade A recommendations in the guidelines should be interpreted as Recommended and the grade B recommendations as Suggested.
The final document was reviewed by the Committee members as well as by other external experts.
DIAGNOSIS AND MANAGEMENT OF COMMUNITY ACQUIRED PNEUMONIA (CAP)
What is the Role of Chest Radiograph in the Diagnosis of CAP? 1 . Wherever feasible, a chest radiograph should be obtained in all patients suspected of having CAP (1A).
2. In the absence of availability of chest radiograph, patients may be treated on the basis of clinical suspicion (3A).
3. Chest radiograph should be repeated if the patient is not improving and also for all those patients who have persistence or worsening of symptoms/physical signs or those in whom an underlying malignancy needs to be excluded. It is not routinely necessary to repeat a chest radiograph in patients who have improved clinically (2A).
What is the Role of Computed Tomography (CT) in the Diagnosis of CAP?
1. CT of the thorax should not be performed routinely in patients with CAP (2A).
2. CT of the chest should be performed in those with non-resolving pneumonia and for the assessment of complications of CAP (2A).
Which Microbiological Investigations Need to be Performed in CAP?
Blood cultures
1. Blood cultures should be obtained in all hospitalised patients with CAP (2A). 2. Blood cultures are not required in routine outpatient management of CAP (2A).
Sputum Gram stain and cultures
1. An initial sputum Gram's stain and culture (or an invasive respiratory sample as appropriate) should be obtained in all hospitalised patients with CAP (2A). 2. Sputum quality should be ensured for interpreting Gram stain results (2A).
3. Sputum for acid-fast bacilli (AFB) should be obtained as per Revised National Tuberculosis Control Programme (RNTCP) guidelines for nonresponders (UPP).
Pneumococcal antigen detection
Pneumococcal antigen detection test is not required routinely for the management of CAP (2A).
Pneumococcal polymerase chain reaction (PCR)
Pneumococcal PCR is not recommended as a routine diagnostic test in patients with CAP (1A).
Legionella antigen detection
Legionella urinary antigen test is desirable in patients with severe CAP (1B).
Other atypical pathogens
Investigations for atypical pathogens like Mycoplasma, Chlamydia and viruses need not be routinely done (2A).
What General Investigations are Required for Patients with CAP?
1. For patients managed in an out-patient setting, no investigations are routinely required apart from a chest radiograph (3A). 2. Pulse oximetry is desirable in out-patients (2B). 3. Pulse oximetric saturation, if available, should be obtained as early as possible in admitted patients (2A). Arterial blood gas analysis should be performed in those with an oxygen saturation ≤90% and in those with chronic lung disease (3A). 4. Blood glucose, urea and electrolytes should be obtained in all hospitalised patients with CAP (3A). 5. Full blood count and liver function tests are also helpful in the management of patients with CAP (3B).
What is the Role of Biomarkers in the Diagnosis of CAP?
Procalcitonin and C-reactive protein need not be performed as routine investigations for the diagnosis of CAP (2A).
Should Patients with CAP be Risk Stratified? What Should be the Optimum Method of Risk Stratification?
1. Patients with community acquired pneumonia should be risk stratified [ Table 2 ] (1A).
2. Risk stratification should be performed in two steps ( Figure 1 ) based upon the need for hospital admission followed by the assessment of the site of admission (non-intensive care unit (ICU) versus ICU). Accordingly, patients can be managed as either out-patient or in-patient (ward or ICU) (1A).
3. Initial assessment should be done with CRB-65. If the score is >1, patients should be considered for admission (1A).
4. Clinical judgement should be applied as a decision modifier in all cases (3A).
5. Pulse oximetry can be used to admit hypoxaemic patients (2A). Hypoxaemia is defined as pulse oximetric saturation ≤92% and ≤90% for age ≤50 and ≥50 years, respectively (3A).
6. Patients selected for admission can be triaged to the ward (non-ICU/ICU based upon the major/minor criteria outlined in table 2 (2A).
7. If any major criterion or ≥3 minor criteria are fulfilled, patients should generally be admitted to the ICU (1A).
What Practices are Recommended Regarding Use of Antibiotics in CAP?
Antibiotics should be administered as early as possible; timing is more important in severe CAP (2A).
What Should be the Antibiotic Therapy in the Out-patient Setting?
1. Therapy should be targeted towards coverage the most common organisms, namely Streptococcus pneumoniae [ Table 3 ] (1A).
2. Out-patients should be stratified as those with or without comorbidities (3A).
3. Recommended antibiotics [ Table 4 ] are oral macrolides (e.g. azithromycin) or oral β-lactams (e.g., amoxicillin 500-1000 mg thrice daily) for out-patients without comorbidities (1A). Table 5 ], oral combination therapy is recommended (β-lactams plus macrolides) (1A).
For out-patients with comorbidities [
5. There is insufficient evidence to recommend tetracyclines (3B).
6. Fluoroquinolones should not be used for empirical treatment [ Table 6 ] (1A).
7. Antibiotics should be given in appropriate doses to prevent emergence of resistance (1A).
What Should be the Antibiotic Therapy in the Hospitalised Non-ICU Setting?
1. The recommended regimen is combination of a β-lactam plus a macrolide (preferred betalactams include cefotaxime, ceftriaxone and amoxicillin-clavulanic acid) (1A).
2. In the uncommon scenario of hypersensitivity to β-lactams, respiratory fluoroquinolones (e.g., levofloxacin 750mg daily) may be used if tuberculosis (TB) is not a diagnostic consideration at admission (1A). Patients should also undergo sputum testing for AFB simultaneously if fluoroquinolones are being used in place of β-lactams. What Should be the Antibiotic Therapy in ICU Setting? 
What is the Role of Biomarkers in the Treatment of CAP?
Biomarkers should not be routinely used to guide antibiotic treatment as this has not been shown to improve clinical outcomes (1A).
What Adjunctive Therapies are Useful for the Management of CAP?
1. Steroids are not recommended for use in nonsevere CAP (2A). 2. Steroids should be used for septic shock or in acute respiratory distress syndrome (ARDS) secondary to CAP according to the prevalent management protocols for these conditions (1A). 3. There is no role of other adjunctive therapies (anticoagulants, immunoglobulin, granulocytecolony-stimulating factor, statins, probiotics, chest physiotherapy, antiplatelet drugs, over-thecounter cough medications, β2-agonists, inhaled nitric oxide and angiotensin-converting enzyme inhibitors) in the routine management of CAP (1A). 4. CAP-ARDS and CAP leading to sepsis and septic shock should be managed according to the standard management protocols for these conditions (1A).
5. Non-invasive ventilation may be used in patients with CAP and acute respiratory failure (2A).
What is the Role of Immunisation and Smoking Cessation for Prevention of CAP?
1. Routine use of pneumococcal vaccine among healthy immunocompetent adults for prevention of CAP is not recommended (1A). Pneumococcal vaccine may be considered for the prevention of CAP in special populations who are at high risk for invasive pneumococcal disease [ Table 7 ] (2A). 2. Influenza vaccination should be considered in adults for the prevention of CAP (3A). 3. Smoking cessation should be advised for all current smokers (1A).
DIAGNOSIS AND MANAGEMENT OF HOSPITAL-ACQUIRED PNEUMONIA (HAP)/VENTILATOR-ASSOCIATED PNEUMONIA (VAP)

What is the Utility of Health-care Associated Pneumonia (HCAP)?
The risk stratification regarding acquisition of multidrug-resistant (MDR) pathogen [ Table 8 ] should be individualised rather than using an umbrella definition of HCAP for this purpose (UPP).
What is the Micro-organism Profile of HAP/ VAP?
Gram-negative bacteria are the most common pathogens causing HAP/VAP in the Indian setting (UPP), and should routinely be considered as the most common aetiological agents of HAP/VAP [ Table 9 ].
What is the Approach to Diagnosis of HAP/VAP?
1. HAP/VAP can be clinically defined using modified Centers for Disease Control and Prevention (CDC) criteria [ 
What is the Role of Biomarkers in Diagnosis of HAP/VAP?
1. Currently available biomarkers should not be used to diagnose HAP/VAP (1A). 2. Where available, serum procalcitonin levels <0.5 ng/mL may help in differentiating bacterial HAP/VAP form other non-infective aetiologies, and may help in decisions for antibiotic cessation (2B).
Is Combined Clinico-bacteriological Strategy Better than Either Strategy Used Alone?
Both clinical and bacteriological strategies can be combined to better diagnose and manage HAP and VAP (UPP).
How do We Decide on the Empiric Antibiotic
Regimen to be Started in a Case of Suspected HAP/VAP?
1. Every ICU/hospital should have its own antibiotic policy for initiating empiric antibiotic therapy in HAP based on their local microbiologic flora and resistance profiles (1A). This policy should be reviewed periodically.
2. In hospitals that do not have their own antibiotic policy, the policy given in these guidelines is recommended (3A). However, they should strive towards formulating their own antibiotic policy.
What is the Role of Routine ETA culture Surveillance?
Routine ETA culture is not recommended. An antibiogram approach should be followed wherever feasible (2A).
Is There a Benefit of Combination Therapy Over Monotherapy for the Treatment of HAP/VAP and HCAP?
Although there is no evidence to suggest that combination therapy is superior to monotherapy, the expert group recommended initial empiric therapy as a combination due to the high prevalence rates of MDR pathogens ( Figure 2 ) in late-onset HAP/VAP, [ Table 11 ] and with an aim to ensure the chances of appropriateness of the initial regimen (UPP). However, once the culture reports are available, the regimen should be de-escalated to the appropriate monotherapy (1A).
What is the Recommended Strategy for Initiating Antibiotics in Suspected HAP/VAP?
1. In patients with suspected HAP, antibiotics should be initiated as early as possible after sending the relevant samples for culture (1A What is the Optimal Duration of Antibiotic Therapy?
1. In patients with VAP due to Pseudomonas, Acinetobacter and methicillin-resistant Staphylococcus aureus (MRSA), a longer duration (14 days) of antibiotic course is recommended (1A). Assessment of CPIS at day 7 may identify patients in whom therapy could be stopped early (2A). 2. In other patients with VAP who are clinically improving, a 7-day course of antibiotics is recommended (1A).
Is Continuous Infusion of Antibiotics Better than Intermittent Doses?
Antibiotic administration in critically ill patients according to their pharmacokinetic/pharmacodynamic profile [ Table 13 ] is recommended as it is associated with superior clinical outcomes (2A).
What is the Role of Inhaled Antibiotics in the Treatment of VAP?
1. Aerosolised antibiotics (colistin and tobramycin) may be a useful adjunct to intravenous antibiotics in the treatment of MDR pathogens where toxicity is a concern (2A). 2. Aerosolised antibiotics should not be used as monotherapy and should be used concomitantly with intravenous antibiotics (2A).
Should one Treat Ventilator Associated Tracheobronchitis (VAT)?
Patients with proven VAT should not be treated with antibiotics (2A 
How to treat MDR Pseudomonas Infections?
For the treatment of MDR Pseudomonas, we recommend initial combination chemotherapy with a carbapenem and either a fluoroquinolone or aminoglycoside (1A). Treatment should then be deescalated to appropriate monotherapy.
What are the Other Good Practices to be Followed in the ICU?
1. Stress ulcer prophylaxis: Sucralfate should be used in patients with HAP while H-2 receptor antagonists or proton pump inhibitors should be used in patients with VAP.
Early enteral feeding:
Enteral feeding is superior to parenteral nutrition and should be used whenever tolerated and in those without any contraindications to enteral feeding.
Deep venous thrombosis (DVT) prophylaxis: DVT
prophylaxis with unfractionated heparin (5000 U thrice a day) or a low molecular weight heparin should be routinely used in all ICU patients with no contraindications to prophylactic anticoagulation.
Glucose control:
A plasma glucose target of 140-180 mg/dL is recommended in most patients with HAP/VAP, rather than a more stringent target (80-110 mg/dL) or a more liberal target (180 -200 mg/dL).
Blood products:
Red cells should be transfused at a haemoglobin threshold of <7 gm/dL except in those with myocardial ischaemia and pregnancy. Platelet transfusion is indicated in patients with platelet count <10000/μL, or <20000/μL if there is active bleeding. Fresh frozen plasma is indicated only if there is a documented abnormality in the coagulation tests and there is active bleeding or if a procedure is planned. Meta-analysis of 9 trials Mean duration of delayed diagnosis and treatment of pulmonary tuberculosis in the FQ prescription group was 19.03 days; the odds ratio of developing FQ-resistant Myobacterium tuberculosis strain was 2.7 (95% CI, 1.3-5.6) 
